Advertisement

Journal of Neurology

, 253:iv22 | Cite as

Restless legs syndrome: Diagnostic assessment and the advantages and risks of dopaminergic treatment

  • Birgit HöglEmail author
  • Walter Paulus
  • Peter Clarenbach
  • Claudia Trenkwalder
Article

Abstract

In the past few years, major advances have been made in the field of restless legs syndrome (RLS). New tools have been developed to assess the presence and severity of RLS and its complications. Furthermore new concepts of the phenotype are emerging.

With a high likelihood a slight dopaminergic hypofunction contributes essentially to the pathophysiology of most phenotypes of RLS. Dopaminergic substitution either with L-DOPA or with dopamine agonists ameliorates symptoms in the large majority of patients. Too high of doses of either type of drug may be involved in the development of augmentation caused by treatment-induced alterations in dopaminergic neurotransmission.

Dopaminergic agents are currently the agents of first choice to treat RLS, and large multicenter trials support the evidence of efficacy. Very careful tailoring of the dose is required to avoid the development of treatment complications, specifically augmentation.

Key words

augmentation periodic limb movements (PLM) dopamine receptors spinal iron 

References

  1. 1.
    Abetz L, Arbuckle R, Allen RP, Garcia- Borreguero D, Hening W, Walters AS, Mavraki E, Kirsch JM (2006) The reliability, validity and responsiveness of the International RLS Study Group rating scale and subscales in a clinical trial setting. Sleep Med 7:340–349PubMedCrossRefGoogle Scholar
  2. 2.
    Abetz L, Vallow SM, Kirsch J, Allen RP, Washburn T, Earley CJ (2005) Validation of the Restless Legs Syndrome Quality of Life questionnaire. Value Health 8(2):157–167PubMedCrossRefGoogle Scholar
  3. 3.
    Allen RP, Earley CJ (1996) Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 19:205–213PubMedGoogle Scholar
  4. 4.
    Allen RP, Earley CJ (2001) Validation of the Johns Hopkins restless legs severity scale. Sleep Med 2:239–242PubMedCrossRefGoogle Scholar
  5. 5.
    Allen RP, Kushida CA, Atkinson MJ (2003) RLS QoL Consortium Factor analysis of the International Restless Legs Syndrome Study Group’s scale for restless legs severity. Sleep Med 4(2):133–135PubMedCrossRefGoogle Scholar
  6. 6.
    Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J (2003) Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health; International Restless Legs Syndrome Study Group. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology.A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 4(2):101–119PubMedCrossRefGoogle Scholar
  7. 7.
    Atkinson MJ, Allen RP, DuChane J, Murray C, Kushida C, Roth T (2004) RLS Quality of Life Consortium Validation of the restless legs syndrome quality of life instrument (RLS-QLI): findings a consortium of national experts and the RLS foundation. Qual Life Res 13(3):679–693PubMedCrossRefGoogle Scholar
  8. 8.
    Atlas Task Force of the American Sleep Disorders Association (1993) Recording and scoring of leg movements. Sleep 16:748–759Google Scholar
  9. 9.
    Benes H, Kaulfuss L, Muchalski T, Kohnen R (2005) Validation of an algorithm for the diagnosis of the restless legs syndrome (RLS): the restless legs syndrome diagnostic index (RLS-DI). Sleep 28:A274Google Scholar
  10. 10.
    Benes H, Kohnen R (2004) The Restless Legs Syndrome Diagnostic Index (RLS-DI). Mov Disord 19:S419Google Scholar
  11. 11.
    Bonati MT, Ferini-Strambi L, Aridon P, Oldani A, Zucconi M, Casari G (2003) Autosomal dominant restless legs syndrome maps on chromosome 14q. Brain 126:1485–1492PubMedCrossRefGoogle Scholar
  12. 12.
    Chesson AL Jr, Wise M, Davila D, Johnson S, Littner M, Anderson WM, Hartse K, Rafecas J (1999) Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Report. Standards of Practice Committee of the Academy of Sleep Medicine. Sleep 22:961–968PubMedGoogle Scholar
  13. 13.
    Clardy SL, Earley CJ, Allen RP, Beard JL, Connor JR (2006) Ferritin subunits in CSF are decreased in restless legs syndrome. J Lab Clin Med 147:67–73PubMedCrossRefGoogle Scholar
  14. 14.
    Davis BJ, Rajput A, Rajput ML, Aul EA, Eichhorn GR (2000) A randomized, double-blind, placebo-controlled trial of iron in restless legs syndrome. Eur Neurol 43:70–75PubMedCrossRefGoogle Scholar
  15. 15.
    Earley CJ, Connor JR, Beard JL, Clardy SL, Allen RP (2005) Ferritin levels in the cerebrospinal fluid and restless legs syndrome: effects of different clinical phenotypes. Sleep 28:1069–1075PubMedGoogle Scholar
  16. 16.
    Earley CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP (2000) Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 54(8):1698–1700PubMedGoogle Scholar
  17. 17.
    Earley CJ, Heckler D, Allen RP (2004) The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med 5:231–235PubMedCrossRefGoogle Scholar
  18. 18.
    Ferini-Strambi L, Oldani A, Castronovo V (2001) RLS augmentation and pramipexole long-term treatment. Neurology 56(Suppl 3):A20 (abstract)Google Scholar
  19. 19.
    Ferri R, Zucconi M, Manconi M, et al. (2006) New approaches to the study of periodic leg movements during sleep in restless legs syndrome. Sleep 29: 759–769PubMedGoogle Scholar
  20. 20.
    Garcia-Borreguero D, Högl B, Ferini- Strambi L, Hadjigeorgiou G, Hornyak M, de Weerd A, Happe S, Stiasny Kolster K, Trenkwalder C, Allen R,Kohnen R (2005) Validation of the Augmentation Severity Rating Scale (ASRS): First results from a study of the European Research RLS Group (EU-RLSG). Sleep Med 6(S2):S67Google Scholar
  21. 21.
    Gschliesser V, Brandauer E, Ulmer H, Poewe W, Högl B (2006) Periodic limb movement counting in polysomnography: effects of amplitude. Sleep Med 7: 249–254PubMedCrossRefGoogle Scholar
  22. 22.
    Guilleminault C, Mondini S, Montplaisir J, Mancuso J, Cobasko D, Dement WC (1987) Periodic leg movement, L-dopa, 5-hydroxytryptophan, and L-tryptophan. Sleep 10:393–397PubMedGoogle Scholar
  23. 23.
    Hening W, Allen R, Earley C, Kushida C, Picchietti D, Silber M (1999) The treatment of restless legs syndrome and periodic limb movement disorder. Sleep 22:970–999PubMedGoogle Scholar
  24. 24.
    Hening WA, Allen RP, Earley CJ, Pichietti DL, Silber MH and Restless Legs Syndrome Task Force of Practice Committee of the American Academy of Sleep Medicine (2004) An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 27:560–583PubMedGoogle Scholar
  25. 25.
    Högl B, Garcia-Borreguero D, Gschliesser V, Cabrero B, Kohnen R, Allen RP (2005) On the development of the “Structured Interview for Diagnosis of Augmentation during RLS treatment” (RLS-SIDA): First experiences. Sleep Med 5(S2):S158Google Scholar
  26. 26.
    Högl B, Kiechl S, Willeit J, Saletu M, Frauscher B, Seppi K, Muller J, Rungger G, Gasperi A, Wenning G, Poewe W (2005) Restless legs syndrome: a community- based study of prevalence, severity, and risk factors. Neurology 64:1920–1924PubMedCrossRefGoogle Scholar
  27. 27.
    Högl B, Poewe W (2005) Restless legs syndrome. Curr Opin Neurol 18(4):405–410PubMedCrossRefGoogle Scholar
  28. 28.
    Hornyak M, Feige B, Riemann D, Voderholzer U (2006) Periodic leg movements in sleep and periodic limb movement disorder: Prevalence, clinical significance and treatment. Sleep Med Rev 10:169–177PubMedCrossRefGoogle Scholar
  29. 29.
    Hornyak M, Riemann D, Vorderholzer U (2006) Magnesium therapy in patients with idiopathic restless legs syndrome: A placebo-controlled, randomized, double blind study. Sleep 29:A289Google Scholar
  30. 30.
    Kaplan PW, Allen RP, Buchholz DW, Walters JK (1993) A double-blind placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep 16:717–723PubMedGoogle Scholar
  31. 31.
    Kohnen R, Benes H, Heinrich CR, Kurella B (2002) Development of the disease-specific Restless Legs Syndrome Quality of Life (RLS-QoL) questionnaire. Mov Disord 17(S5):A232Google Scholar
  32. 32.
    Kohnen R, Oertel WH, Stiasny-Kolster K, et al. (2004) Severity rating of RLS: Validation of RLS six scales. Sleep 27:A304Google Scholar
  33. 33.
    Kohnen R, Oertel WH, Stiasny-Kolster K, et al. (2003) Severity rating of restless legs syndrome: review of ten years experience with the RLS-6 scales in clinical trials. Sleep 26:A342Google Scholar
  34. 34.
    Kushida C, Tolson J (2006) Ropinirole is an Effective Treatment for Patients with Restless Legs Syndrome (RLS) Needing Extended Treatment Coverage. Abstract AAN. Neurology 66(Suppl)Google Scholar
  35. 35.
    Lavigne GJ, Montplaisir JY (1994) Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep 17:739–743PubMedGoogle Scholar
  36. 36.
    Lesage S, Hening WA (2004) The restless legs syndrome and periodic limb movement disorder: a review of management. Semin Neurol 24:249–259PubMedCrossRefGoogle Scholar
  37. 37.
    Lugaresi E, Coccagna G, Tassinari CA, Ambrosetto C (1965) Polygraphic data on motor phenomena in the restless legs syndrome. Rivista di Neurologia 35:550–561PubMedGoogle Scholar
  38. 38.
    Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P (1997) Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 12:61–65PubMedCrossRefGoogle Scholar
  39. 39.
    O’Keeffe ST, Gavin K, Lavan JN (1994) Iron status and restless legs syndrome in the elderly. Age Aging 23:200–203Google Scholar
  40. 40.
    Ossipov MH, Lai J, King T, Vanderah TW, Porreca F (2005). Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers 80:319–324PubMedCrossRefGoogle Scholar
  41. 41.
    Paulus W, Schomburg ED (2006) Dopamine and the spinal cord in Restless Legs Syndrome: Does spinal cord physiology reveal a basis of augmentation? Sleep Medicine Reviews 10(3):185–196PubMedCrossRefGoogle Scholar
  42. 42.
    Paulus W, Trenkwalder C (2006) Less is more: Therapy-related augmentation of symptoms in Restless Legs Syndrome caused by dopaminergic overstimulation. Lancet Neurology (in press)Google Scholar
  43. 43.
    Pennestri M, Montplaisir J, Richard M, Rompre S, Colombo R, Lanfranchi PA (2006) Differetial rise of blood pressure in periodic leg movements associated or not with micro-arousals in patients with restless legs syndrome. Sleep 29:A290–291Google Scholar
  44. 44.
    Rye D (2006) What should we be measuring? Defining the “P” in PLMS. Sleep 29:741–742PubMedGoogle Scholar
  45. 45.
    Rye D, Hicks A, Kristjansson K, et al. (2005) Population-based confirmation of the 12q locus in Iceland. Sleep 28:A277–278Google Scholar
  46. 46.
    Santamaria J, Pranzo A, Tolosa E (2003) Development of restless legs sindrome after dopaminergic treatment in a patient with periodic leg movements in sleep. Sleep Med 4:153–155PubMedCrossRefGoogle Scholar
  47. 47.
    Symonds CP (1953) Nocturnal myoclonus. J Neurol Neurosurg Psychiatry 16:166–171PubMedCrossRefGoogle Scholar
  48. 48.
    Trenkwalder C, Paulus W (2004) Why do restless legs occur at rest?—pathophysiology of neuronal structures in RLS.Neurophysiology of RLS (part 2). Clin Neurophysiol 115:1975–1988PubMedCrossRefGoogle Scholar
  49. 49.
    Trenkwalder C, Paulus W, Walters AS (2005) The restless legs syndrome. Lancet Neurol 4:465–475PubMedCrossRefGoogle Scholar
  50. 50.
    Venugopalan VV, Ghali Z, Senecal J, Reader TA, Descarries L (2006) Catecholaminergic activation of G-protein coupling in rat spinal cord: further evidence for the existence of dopamine and noradrenaline receptors in spinal grey and white matter. Brain Res 1070(1):90–100PubMedCrossRefGoogle Scholar
  51. 51.
    Walters AS and The International Restless Legs Syndrome Study Group (1995) Toward a better definition of restless legs syndrome. Mov Disord 10:634–642PubMedCrossRefGoogle Scholar
  52. 52.
    Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, Trenkwalder C (2003) International Restless Legs Syndrome Study Group Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 4(2):121–132PubMedCrossRefGoogle Scholar
  53. 53.
    Winkelman JW (1999) The evoked heart rate response to periodic leg movements of sleep. Sleep 22:575–580PubMedGoogle Scholar
  54. 54.
    Zucconi M, Ferri R, Allen R, Baier PC, Bruni O, Chokroverty S, Ferini-Strambi L, Fulda S, Garcia-Borreguero D, Hening WA, Hirshkowitz M, Högl B, Hornyak M, King M, Montagna P, Parrino L, Plazzi G, Terzano MG (2006) International Restless Legs Syndrome Study Group (IRLSSG), The official World Association of Sleep Medicine (WASM) Standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG). Sleep Med 7:175–183PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff-Verlag 2006

Authors and Affiliations

  • Birgit Högl
    • 1
    Email author
  • Walter Paulus
    • 2
  • Peter Clarenbach
    • 3
  • Claudia Trenkwalder
    • 2
  1. 1.Dept. of NeurologyMedical UniversityInnsbruckAustria
  2. 2.Dept. of Clinical NeurophysiologyGeorg-August University GöttingenGöttingenGermany
  3. 3.Dept. of NeurologyEv. Johannes-KrankenhausBielefeldGermany

Personalised recommendations